[Form 4] Twist Bioscience Corp Insider Trading Activity

Rhea-AI Filing Summary

Paula Green, Senior Vice President of Human Resources at Twist Bioscience Corporation (TWST), reported a sale of 295 shares of TWST common stock on 09/22/2025 at an average price of $27.56 per share, leaving her with 124,542 shares beneficially owned. The filing indicates the sale was a mandatory "sell to cover" transaction to satisfy tax-withholding obligations arising from the vesting of restricted stock units rather than a discretionary trade by the reporting person. The Form 4 was signed by an attorney-in-fact and submitted on 09/24/2025. The transaction is routine for equity compensation settlements and does not, by itself, indicate a change in officer ownership intent.

Insights

Corporate Governance Expert

TL;DR: Routine sell-to-cover after RSU vesting; not a discretionary disposition and typically immaterial to governance.

The Form 4 shows a small, mandated sale of 295 shares to satisfy tax withholding from vested restricted stock units. Such transactions are standard under many equity incentive plans and are usually pre-determined by the issuer's withholding election rather than a signal of insider sentiment. The remaining beneficial ownership (124,542 shares) indicates continued stake alignment with shareholders. No new agreements, departures, or governance actions are disclosed.

Securities Analyst

TL;DR: Transaction is administrative; sale size is minor relative to typical officer holdings and unlikely to affect valuation.

The sale of 295 shares at $27.56 appears to be a tax-related settlement following RSU vesting. The transaction size is small and the filing explicitly states it was required by the issuer's sell-to-cover practice. There is no evidence of a larger, discretionary divestiture or material change in insider ownership position. Investors typically treat these filings as neutral; monitor for any future voluntary sales or pattern changes.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Green Paula

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD.

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP of Human Resources

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/22/2025		S		295(1)	D	$27.56	124,542	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Paula Green	09/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Paula Green (TWST) report on Form 4?

The filing reports a sale of 295 shares of TWST common stock on 09/22/2025 at $27.56 per share, leaving 124,542 shares beneficially owned.

Why were the shares sold according to the Form 4?

The sale was a mandatory 'sell to cover' to satisfy tax-withholding obligations tied to the vesting of restricted stock units, not a discretionary trade.

What is Paula Green's role at Twist Bioscience?

She is identified as Senior Vice President of Human Resources and the Form 4 indicates the filing was by one reporting person.

When was the transaction executed and when was the Form 4 filed?

Transaction date: 09/22/2025. Form 4 signature and submission date: 09/24/2025.

Does this Form 4 indicate a material change in insider ownership?

No. The filing characterizes the sale as a routine tax-withholding transaction and reports a remaining beneficial ownership of 124,542 shares.